May. 7 at 11:34 AM
Baird⬆️the PT on
$MIRM to
$129 (was
$112), reiterated at Outperform, and said: Incrementally positive on earnings after updating its model on the company's beat and raise 1Q.
$IPSEY $CMMB GSK CALT
GILD VIR
Baird added—The 1Q print was a nice top-line beat, driven by continued outperformance from Livmarli and leading management to raise the FY2026 revenues range by
$30M (5%) on both ends of the range.
We think the acquisition of zilurgisertib for FOP is pretty unique, though management has a solid track record of getting good deals on lesser-known assets that end up contributing to the top line.
Given the continued commercial and clinical success, we're raising our price target to
$129/shr.
